Predictors of long-term structural valve deterioration and failure after transcatheter aortic valve implantation

Read full text
Authors: Tullio Palmerini, Francesco Saia, Antonio Giulio Bruno, Marianna Adamo, Giuliano Chizzola, Mauro Massussi, Marco De Carlo, Giulia Costa, Marco Angelillis, Luca Testa, Francesco Bedogni, Bárbara Bellini
+17 more Matteo Montorfano, Nevio Taglieri, Gabriele Ghetti, Mateusz Orzałkiewicz, Giuseppe Bruschi, Bruno Merlanti, Erica Ferrara, Arnaldo Poli, Francesco De Felice, Carmine Musto, Marco Foroni, Laura Lombardi, Alex Conte, Damiano Regazzoli, Adele Pierri, Tiziana Attisano, Nazzareno Galiè
Cited by: 4
References: 19

Abstract

BACKGROUND: Independent predictors and prognostic correlates of structural valve deterioration (SVD) after transcatheter aortic valve implantation (TAVI) have not been investigated beyond 5-year follow-up. AIMS: We aimed to investigate the association between the early residual mean postprocedural gradient (ERMPG) after TAVI and long-term SVD rates as well as the association of SVD with bioprosthetic valve failure (BVF) and 10-year mortality rates. METHODS: Patients with severe aortic valve stenosis enrolled in the Medtronic One Hospital Clinical Service at 10 Italian centres were included in the study. ERMPG was measured with echo-Doppler at hospital discharge or within 3 months from TAVI. RESULTS: Between September 2007 and December 2014, 1,291 patients undergoing TAVI with a CoreValve/Evolut valve met the enrolment criteria of the study. After a median follow-up of 59.4 months, there were 46 patients with SVD (cumulative incidence rate 3.6%). A significant stepwise increase in the risk of SVD was apparent across tertiles of ERMPG (p=0.009), and in the multivariable analysis, ERMPG was an independent predictor of SVD (adjusted subdistribution hazard ratio [sHR] 1.05, 95% confidence interval [CI]: 1.01-1.08; p=0.004). Among the 46 patients with SVD, 25 (54.3%) had or developed BVF. SVD was associated with increased 10-year rates of all-cause mortality (adjusted hazard ratio 2.12, 95% CI: 1.49-3.00; p

Fields of Study & Subjects

Cardiac Valve Diseases and Treatments Cardiovascular Function and Risk Factors Aortic Disease and Treatment Approaches

Publication details

Journal / source
EuroIntervention
Publisher
Europa Digital & Publishing
Volume
22
Issue
2
Pages
e90–e100
Publication date
1 January 2026
Language
EN